Banner Publications MH200828 N141

Publications

Results found: 69

Showing results: 0 - 49

eLife

A powerful drug combination strategy targeting glutamine addiction for the treatment of human liver cancer.

05-10-2020
Life science alliance

The RECQL helicase prevents replication fork collapse during replication stress.

01-10-2020
Gut

CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinoma.

01-04-2020
European journal of immunology

High-throughput compound screen reveals mTOR inhibitors as potential therapeutics to reduce (auto)antibody production by human plasma cells.

01-01-2020
eLife

TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth.

19-12-2019
Nature

Inducing and exploiting vulnerabilities for the treatment of liver cancer.

01-10-2019
Cancer research

Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (ATR) Overcomes Oxaliplatin Resistance and Promotes Antitumor Immunity in Colorectal Cancer.

01-06-2019
The Journal of experimental medicine

Ezh2 inhibition in Kras-driven lung cancer amplifies inflammation and associated vulnerabilities.

03-12-2018
Genome medicine

A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers.

27-11-2018
Journal of hepatology

Phospho-ERK is a biomarker of response to a synthetic lethal drug combination of sorafenib and MEK inhibition in liver cancer.

01-11-2018
Cancer research

Integrative Modeling Identifies Key Determinants of Inhibitor Sensitivity in Breast Cancer Cell Lines.

01-08-2018
Oncogene

ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors.

01-08-2018
Cell reports

Neutrophils Kill Antibody-Opsonized Cancer Cells by Trogoptosis.

26-06-2018
Cell research

A CRISPR screen identifies CDK7 as a therapeutic target in hepatocellular carcinoma.

01-06-2018
Molecular cancer therapeutics

PIM Kinases Are a Potential Prognostic Biomarker and Therapeutic Target in Neuroblastoma.

01-04-2018
Cell reports

High-Throughput Functional Genetic and Compound Screens Identify Targets for Senescence Induction in Cancer.

17-10-2017
European urology

A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.

01-06-2017
Stem cells (Dayton, Ohio)

TRIM28 is an Epigenetic Barrier to Induced Pluripotent Stem Cell Reprogramming.

01-01-2017
Clinical cancer research : an official journal of the American Association for Cancer Research

Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance.

01-11-2016
Methods in molecular biology (Clifton, N.J.)

Pooled shRNA Screening in Mammalian Cells as a Functional Genomic Discovery Platform.

02-09-2016
Oncotarget

Integrated in vivo genetic and pharmacologic screening identifies co-inhibition of EGRF and ROCK as a potential treatment regimen for triple-negative breast cancer.

12-07-2016
Molecular cancer therapeutics

Sensitizing Triple-Negative Breast Cancer to PI3K Inhibition by Cotargeting IGF1R.

01-07-2016
Oncotarget

Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signaling.

21-06-2016
Nature biotechnology

CRISPR knockout screening outperforms shRNA and CRISPRi in identifying essential genes.

01-06-2016
Cell

A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility.

07-04-2016
Oncotarget

An integrated genomic approach identifies that the PI3K/AKT/FOXO pathway is involved in breast cancer tumor initiation.

19-01-2016
Scientific reports

The lethal response to Cdk1 inhibition depends on sister chromatid alignment errors generated by KIF4 and isoform 1 of PRC1.

01-10-2015
Cell reports

PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs.

29-09-2015
Nucleic acids research

Advances in CRISPR-Cas9 genome engineering: lessons learned from RNA interference.

20-04-2015
Bioscience reports

Identification of signalling cascades involved in red blood cell shrinkage and vesiculation.

16-04-2015
Cell research

SMARCE1 suppresses EGFR expression and controls responses to MET and ALK inhibitors in lung cancer.

01-04-2015
Oncogene

A chromatin modifier genetic screen identifies SIRT2 as a modulator of response to targeted therapies through the regulation of MEK kinase activity.

22-01-2015
Cell reports

Parallel in vivo and in vitro melanoma RNAi dropout screens reveal synthetic lethality between hypoxia and DNA damage response inhibition.

20-11-2014
Proceedings of the National Academy of Sciences of the United States of America

Loss of p53 induces cell proliferation via Ras-independent activation of the Raf/Mek/Erk signaling pathway.

21-10-2014
Molecular systems biology

The Good, the Bad, and the Ugly: in search of gold standards for assessing functional genetic screen quality.

01-07-2014
Cell reports

Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3.

10-04-2014
Nature

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.

03-04-2014
Molecular and cellular biology

The corepressor CTBP2 is a coactivator of retinoic acid receptor/retinoid X receptor in retinoic acid signaling.

01-08-2013
Cell

MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling.

21-11-2012
Journal of cellular and molecular medicine

Identification of F-box only protein 7 as a negative regulator of NF-kappaB signalling.

01-09-2012
Nature

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

26-01-2012
The Journal of experimental medicine

A genome-wide RNAi screen in mouse embryonic stem cells identifies Mp1 as a key mediator of differentiation.

19-12-2011
PloS one

The histone demethylase Jarid1b (Kdm5b) is a novel component of the Rb pathway and associates with E2f-target genes in MEFs during senescence.

08-10-2011
Cancer discovery

Functional subtyping of breast cancer.

01-08-2011
Cell

A Genome-wide multidimensional RNAi screen reveals pathways controlling MHC class II antigen presentation.

15-04-2011
Cell cycle (Georgetown, Tex.)

Screening for modulators of cisplatin sensitivity: unbiased screens reveal common themes.

01-02-2011
Future oncology (London, England)

Exploration of synthetic lethal interactions as cancer drug targets.

01-11-2010
IDrugs : the investigational drugs journal

Using large-scale RNAi screens to identify novel drug targets for cancer.

01-11-2010
Molecular cancer research : MCR

Interleukin-1R-associated kinase 2 is a novel modulator of the transforming growth factor beta signaling cascade.

01-04-2010
Clinical cancer research : an official journal of the American Association for Cancer Research

Candidate biomarkers of response to an experimental cancer drug identified through a large-scale RNA interference genetic screen.

15-09-2009

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.